Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Lymphoid 1Dermatologic 1CNS 1

Conditions

Rhabdomyosarcoma 1Osteosarcoma 1Melanoma 1Hodgkin Disease 1Hepatoblastoma 1Glioblastoma 1Fibrolamellar hepatocellular carcinoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Hepatocellular 1

Interventions

fludarabine 4Cyclophosphamide 4pembrolizumab 3Specimen Handling 3aflibercept 2X-Rays 2Nivolumab 2Magnetic Resonance Spectroscopy 2Interleukin-2 2Dasatinib 2Biopsy 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1epacadostat 1entinostat 1dostarlimab 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × dostarlimab × Lymphoid × Clear all
NCT06521567 2025-11-12

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

GlaxoSmithKline

Phase 1/2 Active not recruiting
83 enrolled
CNSDermatologicGastrointestinalLymphoidSarcoma

Fibrolamellar hepatocellular carcinoma, Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Melanoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡